


Welcome to the Oncopeptides OPD5 clinical development plan.

Here you will find an overview of the clinical development plan and a brief review of the study.

OPD5 CLINICAL DEVELOPMENT PLAN



OPD5 is Oncopeptides' second peptide-drug conjugate (PDC) and is under development for high-dose myeloablative conditioning regimen followed by autologous stem cell transplant (ASCT) for patients with multiple myeloma (MM). OPD5 is an analogue to melflufen (INN melphalan flufenamide). In contrast to melflufen, OPD5 has been formulated to meet the requirements for high-dose myeloablative therapy.¹

COAST Study¹

A Phase 1 multicenter study evaluating OPD5 as a myeloablative conditioning regimen in relapsed refractory multiple myeloma (RRMM) (OP-501 COAST)